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Introduction 
 
Ultraviolet B light is a potent environmental carcinogen that elicits a 
characteristic response in skin following an acute exposure.  This response includes: 
generation of reactive oxygen species;  inflammation, marked by cyclooxygenase-2 
(COX-2) induction; DNA damage resulting in an early phase of apoptosis; and the 
induction of a delayed hyperproliferative phase (Soter, 1990; de Gruijl, 1999) (Herrlich et 
al., 1994).  Although mechanistic studies regarding inflammation, apoptosis, and 
proliferation have been widely investigated, regulation of these photobiological events in 
response to UVB is not well established.  This investigation sought to explore the 
regulatory capabilities of the nuclear hormone receptor, Peroxisome Proliferator-
Activated Receptor γ (PPARγ) in response to UVB irradiation. 
The National Cancer Institute estimates more than 1,000,000 new cases of non-
melanoma skin cancer (U.S. NIH, 2008b) and 62,480 new cases of melanoma (U.S. NIH, 
2008a) will be diagnosed in 2008 with approximately 1,000 and 8,420 deaths reported 
from these cancers respectively.  Chronic exposure to UVB can lead to insufficient repair 
of DNA damage resulting in clonal expansion of a mutated cell and ultimately 
malignancy.  Although the inflammatory response, apoptosis, and delayed 
hyperproliferation are not usually carcinogenic processes individually, these UVB-
induced events can act in concert to promote the initiation and development of cutaneous 
malignancies.  It is because of this synergistic activity that it is crucial to identify the 
regulatory molecules and mechanisms associated with acute UVB exposure so that 
effective therapies that target these photobiological effects can be introduced prior to the 
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initiation and development of skin cancer.  Therefore, in this study, we focused on the 
regulation of UVB-induced inflammation, apoptosis, and delayed hyperproliferation by 
the nuclear hormone receptor, Peroxisome Proliferator-Activated Receptor γ (PPARγ).  
Establishing a knowledge base on the characteristics of UVB light, the biological 
results of acute UVB exposure, the relationship between these UVB-induced events and 
cancer initiation and promotion, and the possible therapeutic capacity of UVB light is 
warranted to better understand the primary focus of this study; the regulatory role of 
PPARγ in the epidermis after acute UVB exposure.  Furthermore, an introduction on the 
characteristics of PPARγ, the known relationship of PPARγ to UVB light, and the 
characteristics of the known PPARγ antagonist, GW9662, as well as an explanation of 
the antagonist methodology used in this study, is necessary.  All of the aforementioned 
information will be presented in the subsequent introduction. 
The electromagnetic spectrum is a complete range of electromagnetic radiation 
that is measured by wavelengths.  Ultraviolet light consists of wavelengths that are longer 
than X-rays on the electromagnetic spectrum, but shorter than visible light.  The natural 
source of ultraviolet rays, the sun, emits electromagnetic radiation that can be divided 
into three categories of Ultraviolet light: Ultraviolet A (UVA), Ultraviolet B (UVB), and 
Ultraviolet C (UVC).  UVA consists of wavelengths that fall between 400-320 
nanometers (nm).  UVB light consists of wavelengths that fall between 320-280 nm, and 
UVC consists of wavelengths between 280-100 nm.  Although the most abundant form of 
UV irradiation to human exposure is UVA, UVB light is the most relevant source  
of ultraviolet light to the skin and can be both beneficial and dangerous depending upon 
the amount of exposure.  Of particular interest to this study are the biological effects 
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following an acute exposure to UVB irradiation.  More specifically to this study, the 
acute exposure resulted in a 1500 J/m2 dosage of UVB with a one-time exposure to the 
radiation.  Previous studies have shown unique biological consequences following acute 
UVB irradiation.  These studies have indicated that UVB light results in biological effects 
in the epidermis including inflammatory responses, apoptosis, and delayed 
hyperproliferation and these photobiological events will be discussed in further detail. 
The initial inflammatory response results in physiological changes that occur on 
both the macro and micro scale. The trigger of the basic inflammatory response includes 
invasion of a foreign object into the body such as bacteria.  Depending on the invasion 
site, the immune response will vary as to which cell will be produced.  Phagocytes will be 
released immediately upon invasion of the foreign object.  Once this occurs, the 
appropriate signaling cascade is started.  These signaling cascades begin with cytokine 
release such as interleukins, tumor necrosis factor, gamma interferon, transforming 
growth factor, lymphotoxin, prostaglandins, or histamine.  These cytokines are produced 
by a host of inflammatory cells such as T-cells, macrophages, NK cells, or mast cells. 
The activation of these cytokines will result in certain physiological events. These events 
include induction of proliferation and differentiation of other inflammatory cells, 
induction of antibodies, and an induction of body temperature increase.  On the larger 
physical scale, the release of cytokines will produce the classic inflammatory response 
which is characterized by swelling, redness, and pain in the infected area.  This larger 
effect is a caused by the dilation of blood vessels in the infected area to increase blood 
circulation, which allows more of the inflammatory cells to reach the infected site at a 
faster rate. 
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When the skin, the body’s largest organ, is invaded by a foreign object or is 
assaulted by an environmental element such as UVB, the inflammatory response occurs 
as described above.  Upon UVB exposure, histamine is released and chemical mediators 
known as prostaglandins are produced.  The histamine, produced by mast cells in the 
dermis, will increase vascular dilation and permeability to allow increased inflammatory 
cell infiltrate.  Ultimately this signaling cascade is responsible for the acute inflammatory 
responses such as edema, redness, and pain in the epidermis that  (Soter, 1990).  
Although histamine production is one inflammatory response to UVB exposure, UVB 
light creates reactive oxygen species, which in turn are the intermediates for 
prostaglandin formation, another cytokine that is responsible for an inflammatory 
response in the skin.  Specifically, UVB creates oxidized phospholipids in the cell 
membrane.  One such oxidized phospholipid produced is an oxidized arachidonic acid 
metabolite that is known to be an endogenous activator of PPARγ, 15-Deoxy-∆12,14-
Prostaglandin J2 (Forman et al., 1995).  This pathway could be related to the ability of 
PPARγ to regulate the inflammatory response post-UVB irradiation, due to the fact that 
PPARγ is known to regulate the inflammatory gene expression in other cells such as 
monocytes, macrophages, and T-cells (Jiang et al., 1998; Yang et al., 2000; von Knethen 
A., 2003).  It is known that arachidonic acid is the precursor for production of 
prostaglandins.  Specifically, arachidonic acid is metabolized to the important 
inflammatory mediator, Prostaglandin E2 (PGE2) (Samuelsson et al., 1975) and it was 
shown that induction of PGE2 production occurred as a result of UVB irradiation (Davies 
et al., 1984).  It is also known that PGE2 induces vascular dilation, increased vascular 
permeability and an edema response (Nakanishi et al., 1995).  However, an enzymatic 
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reaction must take place for the oxidized arachidonic acid to produce PGE2.  
Cyclooxygenase-2 (COX-2) is the enzyme that catalyzes the reaction of arachidonic acid 
to PGE2 and has been shown to occur preferentially (Brock et al., 1999).  More 
importantly, it has been shown that  increased PGE2 production is coupled with a marked 
increase in Cox-2 production upon UVB irradiation (Buckman et al., 1998).  Hence, Cox-
2 serves as excellent biomarker to observe inflammatory responses after UVB irradiation 
and is used as such in this study.  Of particular importance to the current investigation is 
the previous study which indicates PPARγ directly or indirectly regulates Cox-2 
expression (Zhang et al., 2005a).  Therefore, PPARγ may be a regulatory molecule of the 
UVB-induced inflammatory response in the skin; an aspect for clarification in the current 
study.  Although UVB-induced inflammation is a prominent photobiological effect, other 
molecular events take place in response to UVB light, such as apoptosis and proliferation. 
  Apoptosis, or programmed cell death can be described as an intended metabolic 
process that occurs as a response to cellular damage.  Apoptosis is a process that was 
initially observed in the mid 1800’s by Carl Vogt, however the topic was not further 
investigated until 1965 when researchers at The University of Queensland in Brisbane 
used electron microscopy to observe this process (Kerr, 1965).  Not long after the 
published report in 1965, the principle researcher, John Foxton Ross Kerr, from The 
University of Queensland, joined with researchers from the University of Aberdeen, 
where they continued to investigate the process of what they called “programmed cell 
necrosis”.  In the article in 1972, “Apoptosis: a basic biological phenomenon with wide-
ranging implications in tissue kinetics”, found in the British Journal of Cancer, the term 
apoptosis was coined (Kerr, 1972).  From the publication of the articles in 1965 and 
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1972, this biological concept has been an active area of study and it has been found that 
improper regulation of the process has implications in ischemic damage and cancer 
initiation and promotion. 
More specifically, the process of apoptosis begins with a traumatic event to the 
cell that begins a signaling cascade to initiate programmed cell death.  The events that 
lead to apoptosis can include viral infection, ionizing radiation, chemotoxic agents, 
irregular expression of apoptotic control mechanisms, and conditions of extreme cellular 
stress.  Furthermore, if the DNA repair control mechanisms cannot be put into action fast 
enough, the cell will immediately begin the process of programmed cell death as a 
defense mechanism.   
It has been demonstrated that UVB irradiation is a source of cellular toxicity.  In 
particular, UVB irradiation causes cellular damage through mutagenic changes in the in 
the DNA such as cyclobutane pyrmidine dimer (CPD) formation and through oxidative 
stress through the production of reactive oxygen species (Sinha, 2002; Sinha RP, 2002).  
UVB light is a critical source of genotoxicity and reactive oxygen species that can cause 
irreparable damage in keratinocytes (de Gruijl, 1999).  This damage leads to apoptotic 
keratinocytes, otherwise known as sunburn cells (Ziegler et al., 1994).  Although there 
are many different signaling cascades that initiate the apoptotic response, depending upon 
the source of cellular stress or toxicity, the progression of apoptosis is the same.  For 
example, the cellular events following a traumatic incident to the cell, including UVB 
irradiation, involve shrinkage of the cell, membrane blebbing, chromosomal 
condensation, and DNA fragmentation (Kulms and Schwarz, 2000).   
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The regulatory relationship between the activation of PPARγ and the process of 
apoptosis is not well established in keratinocytes.  However, there have been studies in 
other cell types that indicate activation of PPARγ inhibits apoptosis.  For example, a 
study involving activation of PPARγ with the thiazolidedione agonist, rosiglitazone, 
inhibited apoptosis in mesangial cells (Efrati et al., 2007).  Root ganglion neurons have 
also been treated with rosiglitazone to activate PPARγ, which has shown to increase the 
anti-apoptotic protein Bcl-2 (Fuenzalida et al., 2007).  However, studies in several 
cancerous cell lines have demonstrated that activation of PPARγ induces apoptosis 
(Vignati et al., 2004; Bonofiglio et al., 2006; Chen et al., 2006).  Although the role of 
PPARγ in epidermal apoptosis has not been elucidated, there has been some preliminary 
evidence showing an indirect regulatory relationship may exist.  Our previous studies 
have shown that blocking PPARγ, upon UVB irradiation, is associated with a significant 
decrease in Cox-2 production indicating PPARγ regulates Cox-2 production (Zhang et 
al., 2005a).  Furthermore, recent studies have shown that Cox-2 inhibitors induce 
apoptosis (Basu et al., 2004; Fan et al., 2006; Liu et al., 2008).  These studies are 
particularly interesting given that our studies indicate a regulatory role of PPARγ on Cox-
2 production.  Hence, PPARγ may be directly or indirectly involved in the regulation of 
apoptosis. 
  Although the complex interplay between the many apoptotic pathways remains 
the primary focus of many investigations, acute UVB exposure is also responsible for an 
increased proliferative phase observed and is observed  in the epidermis 72-96 hours after 
UVB irradiation (Tripp et al., 2003b).     
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An increased proliferative phase is proceeded by a rapid increase in the number of 
cells entering the cell cycle.  The cell cycle consists of five phases which include: G0, G1, 
S, G2, and M phases.  Cells in the G0 phase are in considered to be in the quiescent phase 
or non-dividing stage.  Cells that are in the G1 and G2 phases are not actually undergoing 
cellular division, however, these phases are important for biosynthesis of important 
enzymes and structures for the S phase and M phase of the cell cycle.  The S phase is the 
cell cycle phase in which DNA replication occurs, whereas the M phase consists of 
nuclear and cytoplasmic division of the proliferating cell into two daughter cells.  Cells 
that continually need to be renewed, such as keratinocytes, will undergo the cell cycle 
throughout the lifetime of the organism.  In order for this to occur, there must be 
important regulatory mechanisms associated with the cell cycle. 
Regulatory molecules associated with the cell cycle ensure that no uncontrolled 
cellular growth occurs as well as ensures any damage the cell incurs will be repaired at 
the appropriate cell cycle checkpoint or will be sent to undergo apoptosis.  The regulatory 
molecules that do this are known as cyclins and cyclin dependent kinases (CDKs).  
Cyclins and CDKs work in heterodimer formation through a phosphorylation event by 
the CDK to enter the cell into the appropriate cell cycle phase.  There are many cyclin-
CDK heterodimers which interact to promote the production of target proteins.  These 
target proteins will assist in the cell cycle phase that the cyclin-CDK heterodimer 
regulates.  For example, Cyclin D will heterodimerize through phosphorylation with 
CDK4.  This complex will then promote activation of genes that will produce proteins 
that are necessary for DNA synthesis in the S phase of the cell cycle.  Although, this 
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example illustrates the induction of the cell into the S phase of the cell cycle, there are 
other molecules which are involved in cell cycle checkpoints and inhibition. 
Cell cycle checkpoints prevent the cell from undergoing cell cycle phase changes, so that 
the cell may repair damaged DNA and to confirm the appropriate cell cycle operations 
are taking place.  Once the cell carries out these checkpoints, the cell will proceed to the 
next cell cycle phase.  The cell also possesses cell cycle inhibitors which prevent the cell 
from entering the cell cycle.  These genes, in essence, prevent the cell from tumor 
formation and are known as tumor suppressor genes.  In regards to cellular proliferation, 
it is extremely important that all regulatory mechanisms, whether they induce, check or 
inhibit the cell cycle, function properly.  If the balance between these regulatory 
processes is askew, the possibility for tumor formation increases dramatically.   
In this study, as found in previous studies, UVB irradiation induces gene 
expression of growth factors that regulate cellular proliferation (Herrlich et al., 1994).  
For example, UVB activates mitogenic signals such as mitogen activated protein kinase 
(MAPK) through signal transduction cascades.  Additionally, epidermal growth factor 
receptor (EGFR) activation is an elicited UVB response (El-Abaseri et al., 2006).  It has 
also been shown that UVB irradiation results in prymidine dimer formation that may lead 
to mutations occurring in the genes that regulate cellular proliferation (de Gruijl et al., 
2001).  Furthermore, it has been shown that if UVB irradiation mutates a cell at the time 
of proliferation and the damaged DNA is not repaired, this mutation may be passed on to 
the daughter cells resulting in unregulated cellular proliferation and possible subsequent 
tumor formation (de Gruijl, 1995).  This increase in cellular proliferation due to UVB 
irradiation disrupts the balance of the cell cycle progression and plays an important role 
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in tumor promotion and development in epidermal carcinomas.  More importantly, 
studies have shown that activation of PPARγ through agonistic activity mimics low dose 
UVB therapy in patients with psoriasis resulting in improvement of psoriatic lesions.  
This finding agrees with other studies that PPARγ may have antiproliferative 
characteristics. These results would make the hormone receptor a useful target in regards 
to cancer development and promotion events. 
  UVB has been shown to have therapeutic capabilities with cutaneous diseases 
such as psoriasis; possibly due to its immunosuppressive activity and its ability to inhibit 
proliferation and induce apoptosis at low doses (Piskin et al., 2004).  Importantly, our 
previous studies in an epidermoid carcinoma cell line (KB) and in SZ95 sebocytes have 
indicated that UVB exposure activates the nuclear hormone receptor, PPARγ (Zhang et 
al., 2005b; Zhang et al., 2006b). This occurs via the ability of UVB and other oxidative 
stressors to produce oxidized glyercophosphocholines that act as potent agonists to 
PPARγ.  Moreover, inhibition of PPARγ was shown to block UVB-induced COX-2 
expression and Prostaglandin E2 production, which is significant because COX-2 
induction is thought to play a role in UVB-induced inflammation, apoptosis, and delayed 
hyperplasia (Tripp et al., 2003b).  Thus, we reasoned that PPARγ is an important 
mediator of the acute photobiological responses in skin.   
PPARγ, like the related PPARα and PPARβ/δ, are members of the nuclear 
hormone receptor family.  The three different PPAR proteins exhibit both distinct and 
overlapping functional roles, but exhibit differences in ligand specificity.  The 
transcriptional activity of PPARs is dependent on their ability to heterodimerize with 
Retinoid X Receptors (RXR), which in turn bind to Peroxisome Proliferator Response 
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Elements (PPRE) in the promoter region of target genes (Gearing et al., 1993).  Ligand 
binding acts to regulate the ability of these heterodimers to bind to coinhibitor or 
coactivator proteins that regulate transcriptional activity (Kuenzli and Saurat, 2003).   
PPARγ is best known for its ability to regulate lipid and glucose homeostasis 
(Willson et al., 2001).  However, more recent studies indicate a potential role for PPARγ 
in diverse pathologic processes, including atherosclerosis, inflammatory diseases such as 
colitis and psoriasis, and neoplastic development (Su et al., 1999; Kuenzli and Saurat, 
2004; Li et al., 2004; Wang et al., 2006).  These recent studies have indicated that PPARγ 
activation downregulates proinflammatory gene expression in patients with 
atherosclerosis, decreases the inflammatory response in patients with colitis and 
decreases proliferation in patients with psoriasis.  The recent study by Wang et al. also 
demonstrated, in solid cancers and leukemia, that PPARγ activation decreases neoplastic 
development through a decrease in cellular proliferation coupled with an induction of 
apoptosis, an increase in terminal differentiation, and an inhibition of angiogenesis. 
There is emerging evidence that PPARγ plays an important role in cutaneous 
biology through PPARγ agonists by inducing anti-inflammatory, pro-apoptotic, and anti-
proliferative effects in epidermis and keratinocytes (Kuenzli and Saurat, 2003).  But there 
is limited evidence demonstrating the biological outcome of these effects when PPARγ is 
activated through agonists produce by UVB irradiation.  Because of the lack of 
information, the focus of this investigation was to clarify the role of PPARγ in regulating 
the inflammatory response, apoptosis and delayed hyperproliferation upon UVB 
irradiation.  In order to proceed with this investigation, however, there was one issue that 
was of concern to this study and has plagued many studies of PPARγ function. 
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The concern that plagues many PPARγ investigations is that many PPARγ 
agonists exhibit PPARγ-independent functions (Galli et al., 2004; He et al., 2006).  
However, the ability to differentiate between PPARγ-dependent and independent effects 
has been markedly improved with the development of the potent, specific, and 
irreversible PPARγ inhibitor, 2-chloro-5-nitrobenzanilide (GW9662) (Leesnitzer et al., 
2002).  GW9662 was discovered through a competition binding assay to covalently bind 
to Cys285 of the PPARγ ligand binding domain and results in specific inhibition of 
PPARγ, but not PPARα or PPARβ/δ, transcriptional activity (Leesnitzer et al., 2002).  In 
addition, GW9662 has been shown to inhibit PPARγ in many cell-based assays and 
animal models and is widely used to verify the specificity of PPARγ-ligand activity 
(Chen et al., 2004; Sivarajah et al., 2005; Nakano et al., 2006).  Furthermore, our 
previous studies using two different cell lines, have shown that the use of both GW9662 
and the dominant negative PPARγ (∆PPARγ) construct produce equivalent results 
(Zhang et al., 2005a; Zhang et al., 2006a). 
Given that we have shown that PPARγ is a target of UVB irradiation and thus is a 
potential regulator of the photoresponse, we sought to determine the role of PPARγ in 
acute UVB-induced epidermal inflammation, apoptosis, and proliferation.  We examined 
this using the PPARγ antagonist, GW9662, in the epidermis of SKH1 mice for three 
reasons.  First, we have shown that UVB-induces PPARγ ligand production, therefore the 
use of exogenous ligands would likely result in a minimal response.  Second, previous 
studies have indicated a potential for PPARγ-independent effects with the use of agonists.  
Third, our previous studies with the ∆PPARγ approach have validated the use of 
GW9662 in blocking PPARγ-dependent effects following acute UVB irradiation in vitro.  
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In the current studies, we show that topical application of GW9662 inhibits UVB-induced 
inflammation and COX-2 expression, and augments both UVB-induced apoptosis and 
proliferation in hairless, albino mouse epidermis.  These data provide clear evidence that 
UVB-induced PPARγ activation is an important regulator of the acute UVB-induced 
cellular response.    
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Materials and Methods 
 
Materials 
GW9662 (2-Chloro-5-nitrobenzanilide), (Cayman Chemical, Ann Arbor, MI).  Murine 
COX-2 and GAPDH RT2 primers, first-strand synthesis and SYBR Green qRT-PCR 
reagents were purchased from SuperArray Bioscience Corp (Frederick, MD).  Unless 
otherwise indicated, all reagents and antibodies for immunohistochemistry were obtained 
from Biocare Medical (Concord, CA). 
 
Animals 
Hairless, albino, female SKH1 mice were purchased from Charles Rivers Laboratories 
(SKH1-Hrhr; Wilmington, MA). The mice were housed in standard microisolator cages 
under a simulated 12 hour day/night cycle and were fed and watered ad libitum. All 
mouse studies were approved by the Indiana University-Purdue University Indianapolis 
Animal Care and Use Committee. SKH1 mice are immunocompetent mice that have a 
defect in hair follicle cycling leading to loss of hair production following the first hair 
cycle, but otherwise exhibit normal epidermal structure (Panteleyev et al., 1998). This 
mouse model is routinely used as the preferred mouse strain for acute and chronic 
photobiology and photocarcinogenesis experiments (Tripp et al., 2003a). 
 
UV irradiation study 
The dorsal skin of SKH1 hairless mice was pre-treated with 100 µl of GW9662 (0.01 
mM, 0.1 mM, 1.0 mM) solubilized in 70% propylene glycol:30% ethanol for 1.5 hours 
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prior to UVB irradiation.  Following pretreatment, the dorsal skin was wiped gently 3 
times with cotton swabs soaked in 100% ethanol to remove non-absorbed reagents.  The 
mice were then immobilized by intraperitoneal (ip) injection with 250 µl of a 1:10 
dilution of Ketamine 1000 mg/Xylazine 142 mg in normal, sterile NaCl.  Once 
immobilized, the mice were irradiated with 1500 J/m2 of UVB light using two 
Westinghouse FS40 sunlamps (National Biological Corp., Twinsberg, OH) (Fischer, 
1999).  A Kodacel filter (Kodak, Rochester, NY) was used to block UVC irradiation. 
UVB fluence was measured at a fixed distance equivalent to the distance between the UV 
lamps and the mouse dorsum prior to each experiment using an IL1700 radiometer 
equipped with a SED240 UVB detector (International Light, Newburyport, MA).  The 
time of exposure for irradiation was calculated from the intensity (fluence) of the lamp 
and the required UVB dose.  Immediately following irradiation, 50 µl of the appropriate 
GW9662 dose was reapplied to the dorsal skin of the mouse.  Prior to excision, the dorsal 
midline was marked with an impermeable marker along the spinal axis.  At each 
experimental time point, the dorsal skin was then excised and bisected along the midline 
and a portion was snap frozen for skin thickness measurements (see below).  The 
remaining half was divided into two sections.  The first section was placed in RNAlater 
(Qiagen, Valencia, CA), the second formalin-fixed in 10% neutral buffered formalin for 
paraffin-embedding and histologic assessment and immunohistochemical analysis.  It 
should be noted that initial studies also included a dose of 10 mM GW9662.  However, 
studies using 10 mM GW9662 were discontinued when it was determined that this dose 
had a modest sunblock effect, possibly as a result of incomplete solubilization, as 
GW9662 absorbs primarily in the UVC range (λmax = 261 nm).  Doses of GW9662 at or 
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below 1 mM had no significant sunblock effect (< 5%), as determined by measuring the 
ability of 100 µl of GW9662 to block UVB transmission when it was applied to a 
Kodacel filter (using a surface area equivalent to the application area used in the mouse 
studies) (not shown).  This lack of sunblock effect was also seen by measuring the 
inability of GW9662 at doses of 1 mM and below to block UVB-induced cyclobutane 
dimer formation (30 minutes post UVB) (not shown). 
 
RNA isolation and COX-2 quantitative RT-PCR 
RNA isolation was performed using the RNeasy kit (Qiagen) according to the 
manufacturer’s protocol.  Following first-strand DNA synthesis, quantitative RT-PCR 
(qRT-PCR) was performed using primers specific to murine COX-2 and GAPDH using a 
Cepheid Smart Cycler® real-time PCR instrument (Fisher Scientific, Pittsburgh, PA). 
COX-2 qRT-PCR results were normalized to GAPDH using the ∆∆Ct method (ABI, 
1997). 
 
Skin thickness determination 
The thickness of the snap frozen dorsal skin sections bisected at the midline was 
measured with a digital caliper by five random measurements taken along the midline cut 
edge. 
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Immunohistochemistry for activated Caspase-3, Ki-67, and phospho-Histone H3 (Ser 
10)(pHH3) 
Mouse dorsal skin sections were formalin-fixed in 10% neutral buffered formalin for 3 
hours and changed to 70% EtOH, trimmed and placed in cassettes for further processing 
and embedding.  Standard deparaffinization and hydration were performed followed by 
heat-induced antigen retrieval using Borg Decloaking Solution (Activated caspase 3) or 
10mM citrate buffer (Ki-67 and pHH3), in a standard kitchen 8 qt programmable pressure 
cooker for 15 minutes using the high setting.  Sections were incubated with Peroxoblock 
(Zymed Laboratories, San Francisco, CA) for two minutes at room temperature.  For 
activated caspase 3 IHC, the sections were then washed with TBS and primary antibody 
(1:100 dilution of rabbit anti-human cleaved caspase-3) was applied in TBS with 1% 
bovine serum-albumin and incubated for 2 hours at room temperature.  For alkaline 
phosphatase conjugation, the Mach 3 kit probe and polymer was added to the sections for 
15 minutes at room temperature. Vulcan Fast Red was used for substrate detection. 
Sections were then counterstained and mounted.  For Ki-67, sections were washed with 
PBS followed by incubation with Ki-67 (SP6) (Lab Vision, Fremont, CA) for thirty 
minutes at room temperature at a 1:1000 dilution in 0.1% bovine serum albumin/PBS.  
For pHH3, sections were washed with PBS and incubated overnight at 4oC with Phospho-
Histone H3 (Ser10) (Cell Signaling Technology, Danvers, MA) at 1:100 dilution in 5% 
normal goat serum/PBS.  In both cases, the sections were then washed and incubated with 
Super Picture HRP Polymer Conjugate Rabbit Primary (Zymed Laboratories) for ten 
minutes at room temperature.  DAB+ (Dako Cytomation) was used for substrate 
detection.  Sections were counterstained and mounted. 
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Quantification of positive cells by IHC and statistical analysis 
Ten random fields were counted in all slides, at either 200 or 400x total magnification, in 
a blinded manner for each condition using a Nikon Eclipse E400 microscope (Nikon 
Corp., Melville, NY).  Data was plotted using GraphPad Prism 4.0. and statistics 
performed using the student t-test using a statistical significance cutoff of p < 0.05. 
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Results 
 
Effects of GW9662 on inflammation: 
Both Cox-2 and subsequent PGE2 production are important mediators of the 
UVB-induced erythema and inflammatory response.  Thus, UVB-induced COX-2 
induction serves as an appropriate marker for UVB-induced inflammatory responses.  We 
have previously determined that GW9662 treatment and the expression of a dominant 
negative construct both inhibit UVB-induced COX-2 expression and/or PGE2 production 
in two different human cell lines.  We therefore examined whether GW9662 pretreatment 
would alter UVB-induced COX-2 expression in murine skin.  Previous studies by others 
have shown that UVB-induced COX-2 expression peaks at approximately 24 hours in 
SKH1 mouse epidermis after a similar UVB dose (Tripp et al., 2003a).  Moreover, COX-
2 induction is sustained through the period of peak hyperproliferation at 72 hours (Tripp 
et al., 2003a).  We therefore examined COX-2 mRNA expression by qRT-PCR at 24 hrs 
(Fig. 1A) & 72 hrs (Fig. 1B) post-UVB irradiation.  At 24 hours, UVB irradiation 
induced a marked increase in Cox-2 production in the UVB control mice, as would be 
expected.  Importantly, there was a significant dose-dependent decrease among all 
GW99662 treated mice (0.01 mM, 0.1 mM, and 1.0 mM).  The most dramatic decrease in 
Cox-2 mRNA expression was seen at the 1.0 mM GW9662 dose, with UVB-induced 
COX-2 induction suppressed by 80%.  At this dose (1 mM), GW9662 had no significant 
effect on COX-2 expression in non-irradiated controls at 24 hrs.  At 72 hours post-UVB, 
Cox-2 expression was again seen to be induced upon UVB irradiation, but only the 
1.0mM GW9662 treated mice showed a significant 77% decrease in the amount of Cox-2 
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mRNA expression versus the vehicle control UVB irradiated mice.  The lowest dose 
tested, 0.01 mM GW9662, resulted in an insignificant increase in UVB-induced COX-2 
mRNA expression levels.  The intermediate dose resulted in an intermediate reduction in 
UVB-induced COX-2 expression, although the decrease did not reach statistical 
significance.  In non-irradiated controls, 1 mM GW9662 also suppressed COX-2 
expression at 72 hrs, although this decrease did not reach statistical significance. 
In addition to COX-2 induction, UVB irradiation of mouse epidermis results in a 
characteristic early edema response (24 hrs) followed by inflammatory cell infiltration of 
the dermal compartment that peaks at 48-72 hours post UVB irradiation (Hammerberg et 
al., 1996).  In Fig. 2, we examined UVB-inflammation using an assessment of skin 
thickness.  Twenty-four hours after irradiation (Fig. 2A), UVB induced an expected 
increase in skin thickness compared with the vehicle control mice.  However, there were 
no significant differences seen between the UVB and GW9662 treated mice.  At 72 hours 
post UVB irradiation (Fig. 2B), UVB again induced an increase in inflammation 
compared with non-irradiated control mice.  Importantly, there was a significant 71% 
increase in skin thickness among the 0.01mM GW9662 and 0.1mM GW9662 treated 
mice over that seen with the UVB-irradiated control mice.  In contrast, pretreatment with 
1.0 mM GW9662 prior to UVB irradiation essentially reduced the skin thickness to non-
irradiated control levels.  It should be noted that no significant change in skin thickness 
was noted in non-irradiated mice treated with the highest dose of GW9662 (1 mM), either 
at 24 or at 72 hrs (not shown). 
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Topical GW9662 induces a dose-dependent augmentation of UVB-induced Apoptosis 
UVB damage triggers numerous, downstream events which can lead to apoptotic 
Keratinocytes:  
The UVB-induced apoptotic response in the epidermis was observed by 
quantification of activated caspase-3 positive cells as seen in Fig. 3.  Caspase-3 is a 
protease that cleaves a specific substrate which induces DNA fragmentation in the 
apoptosis pathway (Liu et al., 1997).  Peak caspase-3 activity, post-UVB irradiation, 
takes place at 24 hours (Assefa et al., 2000) thus, activated caspase-3 cells were 
quantified at this time point.  As expected, there was a significant induction of UVB-
induced apoptosis versus the non-irradiated controls.  There was also a dose-dependent 
increase in the apoptotic response seen in the GW9662 treated epidermis versus the UVB 
control (22%, 112%, and 173% for 0.01, 0.1, and 1 mM GW9662 respectively).  This 
augmented apoptotic response reached statistical significance for both the 0.1 and 1 mM 
doses.  To rule out any physical sunblock effect, we also examined whether systemic 
administration of GW9662 could also augment UVB-induced apoptosis.  Importantly, we 
show that there was also a dose-dependent increase in apoptotic cells in mice treated by 
intraperitoneal injection of GW9662 versus UVB control (61% and 173% for 1 & 5 
mg/kg respectively); this increase in apoptosis relative to UV control mice reached 
statistical significance for the 5 mg/kg dose.  Assuming 80% body water, 100% tissue 
bioavailability, and a weight of 25 gm, this dose is equivalent to approximately 25 µM 
GW9662.  The presence of activated caspase-3 activity in the sebaceous gland(Akasaka 
et al.) served as a positive internal control (Fig. 3C). 
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Topical GW9662 treatment augments UVB-induced delayed hyperproliferation as 
assessed by epidermal thickness (hyperplasia), Ki-67 immunolabeling and Phospho-
Histone H3 (Ser10) immunolabeling: 
UVB results in delayed hyperproliferation in the epidermis of SKH1 mice, which 
is observed 72-96 hours after a similar dose of UVB (Tripp et al., 2003a).  Moreover, 
UVB-induced COX-2 induction is necessary for this hyperplastic response (Tripp et al., 
2003a).  However, PPARγ agonists have been shown to have antiproliferative effects in 
human and mouse epidermis (Ellis et al., 2000).  Given that we show that GW9662 
blocks UVB-induced promitogenic COX-2 expression, we were particularly interested in 
examining the affects of GW9662 on this delayed hyperplastic response.  We first 
evaluated the ability of GW9662 to alter UVB-induced epidermal hyperplasia by 
assessing epidermal thickness (Fig. 4A).  Interestingly, GW9662 resulted in 
augmentation of UVB-induced hyperplasia.  However, this augmentation exhibited an 
inverse dose-response effect, with 0.01 mM GW9662 exhibiting the greatest effect (64% 
increase in epidermal thickness compared with UV control skin), compared with a non-
significant 22% and 9.6% increase for 0.1 and 1 mM GW9662 treated skin, respectively.  
Treatment with 1 mM GW9662 in the absence of UVB-irradiation had no significant 
effect on epidermal thickness (not shown). 
We next assessed hyperproliferation through two different markers, Ki-67 and 
phosphohistone H3 (ser10) at 72 hours post-UVB irradiation. Ki-67 is a nuclear protein 
that serves as a proliferation marker and is only expressed during late G1, S, M, and G2 
phases (Gerdes et al., 1984).  In Fig. 4B, quantification of Ki-67 positive cells at 72 hours 
post UVB indicated that there was a significant increase in UVB-induced proliferation in 
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GW9662 treated epidermis.  As for epidermal thickness, this response exhibited an 
inverse dose-response curve: the greatest response was seen at the lowest dose tested, 
0.01 mM GW9662 (93% increase in Ki-67 immunolabeling compared with UV controls), 
while the higher doses were less effective (47% and 45% for the 0.1 and 1.0 mm doses, 
respectively).  Treatment of mouse skin with 1 mM GW9662 had no significant effect on 
Ki-67 expression in the absence of UVB-irradiation (not shown). 
Fig. 5 shows histological staining of positive Ki-67 cells in the epidermis. In the 
positive control gut tissue (Fig. 5A), Ki-67 immunolabeling was restricted to the 
proliferative crypts within the mucosa.  Similarly, in the UVB control epidermis (Fig. 
5C), the increase in the Ki-67 immunoreactivity was seen primarily in the basal layer.  In 
contrast, 0.01 mM GW9662 treated epidermis demonstrated marked Ki-67 
immunopositivity in suprabasal layers of the epidermis, demonstrating expansion of the 
proliferative basal compartment within the epidermis relative to UV controls. This 
expansion of the proliferative compartment was also seen to a lesser degree in the UVB-
irradiated epidermis treated with the higher doses of GW9662 (not shown). 
We also examined proliferation using phospho-Histone H3 (PHH3) 
immunolabeling.  Phosphorylation of serine 10 of Histone H3 tightly correlates with the 
chromosomal condensation that occurs with mitosis (Hendzel et al., 1997).   
A similar 78% increase in UVB-induced proliferation was noted in skin treated with 0.01 
mM GW9662 by counting PHH3 immunopositive cells in the basal layer compartment 
(vehicle control = 3 ± 0.82; UV control = 11 ± 1.56; UV + 0.01 mM GW9662 = 17.22 ± 
2.1 cells / 200 x field: mean and SEM for 4-5 mice).  There was also no significant effect 
on PHH3 expression in the 1 mM GW9662 dose without UVB irradiation (not shown). 
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Discussion 
 
In previous studies, we have shown that PPARγ is a target for UVB-induced 
ligand production through the production of oxidized glycerophosphocholines (Zhang et 
al., 2005a; Zhang et al., 2006a).  In this study, we provide evidence that UVB-induced 
PPARγ activation plays a significant role in the acute cutaneous response to UVB 
irradiation.  This is important, as a previous study has shown that exogenous 
PPARγ ligand exposure has no significant effect on UVB-induced photocarcinogenesis 
(He et al., 2005).  In our initial survey, at 24 and 72 hours post-UVB irradiation, Cox-2 
mRNA levels were significantly decreased when PPARγ was blocked with GW9662, 
with the most effective dose at 1 mM.  This agrees with our previous results in an 
epitheliod carcinoma cell line and in immortalized sebocytes (Zhang et al., 2005a; Zhang 
et al., 2006a).  A similar dose-response curve was seen for the induction of apoptosis, 
suggesting a potential COX-2 dependent mechanism.  However, skin thickness studies 
and proliferation data indicate that UVB-induced PPARγ activation exhibits a more 
complex role in inflammation and delayed hyperproliferative responses. 
In Fig. 2, we show that UVB-induced edema responses at 24 hrs are largely 
unaffected by GW9662.  This is somewhat surprising, since 1 mM GW9662 effectively 
blocks UVB-induced COX-2 expression at the same time-point.  Given that COX-2 
inhibition is known to suppress UVB-induced edema responses in mouse epidermis, it is 
interesting that PPARγ antagonism had no significant effect on this early inflammatory 
response.  If anything, PPARγ antagonism may slightly increase the edema response, 
suggesting that PPARγ has a modest anti-inflammatory effect.  At 72 hours, a biphasic 
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dose-response effect was observed: lower doses of PPARγ significantly increased 
epidermal skin thickness, while the highest dose tested significantly suppressed UVB-
induced inflammation.  The decreased delayed inflammatory response seen at the highest 
dose (1 mM) could possibly be attributed to loss of pro-inflammatory COX-2 signaling. 
However, the increased inflammatory response seen with lower doses of GW9662 are 
likely attributed to anti-inflammatory activity of PPARγ.  The idea that PPARγ acts as an 
anti-inflammatory signal is supported by studies of PPARγ in inflammatory skin disease 
as well as inflammatory diseases in other tissues.  Thus, within the epidermis, 
PPARγ appears to mediate complex effects on inflammation, possibly as a result of 
COX-2 independent and COX-2 dependent signaling. 
In the second aspect of our overview of photobiological responses to UV in  
SKH-1 mouse epidermis, we studied the effect of GW9662 treatment on UVB-induced 
apoptosis and found a significant dose-dependent induction of apoptosis in the GW9662 
treatment groups.  These results suggest that PPARγ activation acts to suppress UVB-
induced apoptosis.  Given that COX-2 induction is thought to suppress UVB-induce 
apoptosis (Liu et al., 1998; Akunda et al., 2007), it is possible that PPARγ regulates UV 
induced apoptosis through COX-2 dependent signaling. 
In our next studies, we examined the role of PPARγ in the characteristic delayed 
hyperproliferative response that is observed following an acute UVB exposure.  Previous 
studies in psoriatic epidermis have indicated that exogenous PPARγ agonist exposure 
exerts an antiproliferative effect, normalizing the hyperplasia associated with this 
inflammatory skin disease (Malhotra, 2005).  However, other studies have shown that 
UVB-induced COX-2 expression is crucial for UVB-induced delayed hyperproliferative 
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response (Rundhaug, 2007).  Thus, it is interesting that GW9662 had an inverse dose-
response affect on delayed hyperproliferation, suggesting that the effects of 
PPARγ activation on proliferation is complex, likely involving COX-2 dependent and 
independent activity.  However, at lower doses, it is clear that GW9662 treatment acts 
primarily to augment UVB-induced hyperproliferation.  This is particularly interesting, 
given that recent studies in epidermal-specific PPARγ knockout mice provide evidence 
that PPARγ acts to suppress tumor promotion in a chemical carcinogenesis mouse model 
(Indra et al., 2007). 
In conclusion, our studies show that topical application of the PPARγ antagonist, 
GW9662, results in variable dose-dependent effects on UVB-induced COX-2 induction, 
inflammation, apoptosis, and proliferation.  Given the important role that UVB-
irradiation plays in skin cancer, as well as its therapeutic use for inflammatory skin 
disease, it is crucial to elucidate the major factors that regulate UVB-induced 
inflammation, apoptosis, and proliferation.  As demonstrated in our study, PPARγ 
provides such a target.  Our findings that GW9662 treatment exhibits complex actions on 
UVB-induced inflammation, apoptosis and particularly proliferation suggest that 
additional mechanistic studies on the pharmacological activities of this compound are 
needed to address potential safety concerns. 
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Fig. 1. Topical application of the PPARγ antagonist (GW9662) suppresses UVB-induced Cox-2 expression. A. SKH-1 mice were 
pretreated with 0.01mM, 0.1mM, 1.0mM GW9662 (GW) for 1.5 hours and irradiated with1500 J/m2 of UVB. A Kodacel filter was 
used to block UVC. Dorsal skin was excised and used for RNA isolation. Each sample for RT-PCR was run in duplicate. Results 
represent the mean and SEM of n = 3-5 mice. B. The same conditions as in section A apply to panel B. Results represent the mean and 
SEM of n=5-7 mice, * p <0.05; ** p <0.01; *** p<0.001, † represents conditions compared to vehicle control, ‡ represents conditions 
compared to UVB control.
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Fig. 2. Effects of topical GW9662 on UVB-induced skin thickness. A. After 1.5hr
pretreatment with GW9662 (0.01mM, 0.1mM, 1.0mM), SKH-1 mice were irradiated with 1500J/m2 of UVB and a Kodacel filter
was used to block UVC. The dorsal skin was excised and immediately snap frozen in Liquid N2. Five random measurements were 
taken along the midline section of the skin with a digital caliper. Results represent the mean and SEM of n = 6-10 mice, **p<0.01, †
represents conditions compared to vehicle control. B. The same conditions and methods were used as in panel A. Results represent
the mean and SEM of n = 3-7 mice, ** p <0.01; *** p<0.001, † represents conditions compared to vehicle control, ‡ represents 
conditions compared to UVB control.
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Fig. 3. The PPARγ antagonist, GW9662, 
augments UVB-induced apoptosis. A.SKH-1 
mice were pretreated with GW9662 (0.01mM, 
0.1mM, 1.0mM) for 1.5 hr and irradiated with 
1500 J/m2. A Kodacel filter was used to block 
UVC. The dorsal skin was excised, fixed in 
10% buffered formalin and paraffin-embedded. 
Results represent the mean and SEM of n = 3-
14 mice for positive activated caspase-3 cells 
per 200x field and were counted in a blinded 
fashion, *** p<0.001, † represents conditions 
compared to vehicle control, ‡ represents 
conditions compared to UVB control. B. This 
represents a positive activated caspase-3 in a 
UVB irradiated SKH-1 mouse. The high power 
image of the positive cell is in the epidermis, 
note the pyknotic nucleus in the inset. C. The 
sebaceous glands in the skin were used as 
positive controls, note the positive pink stain in 
the sebaceous gland, shown by arrows, of a 
vehicle control mouse compared with the 
negative staining of the epidermis shown in 
brackets.
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Fig. 4. UVB-induced delayed hyperplasia is augmented by GW9662 pretreatment. A. GW9662 augments UVB-induced epidermal thickness. 
SKH-1 mice were irradiated with 1500 J/m2 of UVB after a 1.5 pretreatment with GW9662 (0.01mM, 0.1mM, 1.0mM). After 72 hrs, the 
dorsal skin was excised, fixed in 10% buffered formalin, and paraffin-embedded. Epidermal thickness was then measured at 72 hrs in H&E
stained sections by light microscopy using a micrometer, ** p <0.01; *** p<0.001, † represents conditions compared to vehicle control, ‡
represents conditions compared to UVB control. B. GW9662 pretreatment augments UVB induced proliferation as measured by Ki-67 
immunolabeling. Paraffin-embedded mouse skin excised 72 hrs following UVB irradiation were subjected to immunohistochemical analysis 
of Ki-67 as detailed in the methods sections. For each treatment group, Ki-67 positive cells were counted in 10 randomly chosen high power 
fields (400x). Results represent the mean and SEM 28 of Ki-67 + cells/400x field (n = 5 mice). In both A & B, slides were blinded prior to 
analysis, *p<0.05; ** p <0.01, † represents conditions compared to vehicle control, ‡ represents conditions compared to UVB control.
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Fig. 5. GW9662 pretreatment results in proliferative zone expansion in UVB-irradiated SKH-1 epidermis.  Photomicrographs of mouse 
epidermis 72 hrs post UVB were taken after Ki-67 immunohistochemical staining as described in Fig 4 above. A. Positive control gut tissue 
demonstrates strongly positive staining in the proliferative compartment in the deep crypts (brackets). Lack of epithelial staining is noted in 
the differentiated cilial luminal epithelium. 200x, bar = 25 µm. B. Vehicle sham control. Note occasional basal layer immunopositive cells for 
Ki-67. 400x, bar = 25 µm. C. UVB-irradiated vehicle control skin. Note the prominent epidermal hyperplasia and prominent Ki-67 
immunolabeling of basal cells lining the epidermal dermal junction (bracket). 400x. D. UVB-irradiated skin treated with 0.01 mM GW9662. 
Note the expansion of the proliferative basal zone and further increase in epidermal thickness. 400x.
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